| |
Age: Women of any age above menarche can use the LNG IUS. Above the age of 20 years, there is no restriction on the use of the LNG IUS. From menarche to the age of 20 years, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Anatomic Abnormalities: The LNG IUS cannot be used in women with a distorted uterine cavity.
Anemias: The LNG IUS can be used without restrictions in women with thalassemia, sickle cell disease and iron-deficiency anemia.
Breast disease: The LNG IUS can be used without restrictions in women with a benign breast disease or with a family history of cancer. In women with an undiagnosed mass in the breast, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks. The LNG IUS cannot be used in women with current or past breast cancers.
Bariatric Surgery: Women with a history of bariatric surgery can use the LNG IUS without any restriction.
Cervical Cancer: The LNG IUS should not be inserted for a woman who is awaiting treatment for cervical cancer. But in women who have had the LNG IUS inserted before detection of the cancer, the advantages of continuing use of the LNG IUS outweigh the theoretical or proven risks.
Cervical Ectropion: Use without restrictions.
Cervical intraepithelial neoplasia: Advantages generally outweigh the theoretical or proven risks.
Cirrhosis: In mild (compensated) cirrhosis, use without restrictions; in severe (decompensated) cirrhosis, risks outweigh the advantages and the LNG IUS should not be used.
Cholestasis: Women with a history of pregnancy-related cholestasis can use the LNG IUS without any restrictions. In women with a history of oral contraceptive (COC) related cholestasis, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Deep Venous Thrombosis / Pulmonary Embolism: In women with only a family history of DVT, use without restrictions. In women who have a history of DVT/PE (without ongoing anticoagulant treatment), acute DVT/PE or on treatment for at least three months, the advantages of the LNG IUS generally outweigh the theoretical or proven risks. In women undergoing minor surgery and major surgery without prolonged immobilization, use without restrictions. In women undergoing major surgery with prolonged immobilization, the advantages generally outweigh the theoretical or proven risks.
Depressive disorders: Use without restrictions
Diabetes mellitus (DM): In women with a history of gestational DM, use without restriction. In women with diabetes mellitus, the advantages of the LNG IUS outweigh the theoretical or proven risks.
Endometrial cancer: The LNG IUS should not be initiated in a woman with endometrial cancer. However, if the woman develops the cancer at a later stage, the advantages of continuation of the LNG IUS outweigh the theoretical or proven risks.
Endometrial Hyperplasia: The LNG IUS can be used without restrictions.
Endometriosis: The LNG IUS can be used without restrictions.
Epilepsy: The LNG IUS can be used without restrictions.
Gall Bladder disease: in women with gall bladder disease (symptomatic / asymptomatic), the advantages of LNG IUS generally outweigh the theoretical or proven risks.
Gestational trophoblastic disease: The LNG IUS should not be used in women with gestational trophoblastic disease irrespective of the β-HCG levels.
Headaches: Women with non-migrainous headaches can use the LNG IUS without any restrictions. In women with migrainous headaches, the advantages of the LNG IUS generally outweigh the theoretical or proven risks.
HIV: In women with a high risk of contracting HIV and HIV infected women, the advantages of the LNG IUS generally outweigh the theoretical or proven risks. The LNG IUS should not be initiated in a woman with AIDS. However if the woman has received her IUS before developing AIDS, the advantages of continuing the LNG IUS generally outweigh the theoretical or proven risks. In a woman with AIDS and clinically well on therapy, the advantages of the LG IUS generally outweigh the theoretical or proven risks.
Hyperlipidemias: In a woman with hyperlipidemias, the advantages of the LNG IUS generally outweigh the theoretical or proven risks.
Hypertension: Women with adequately controlled hypertension or with elevated blood pressure levels (systolic 140 −159 or diastolic 90 − 99) can use the LNG IUS without restrictions. In women with elevated blood pressure levels (systolic > 160 or diastolic > 100) or with vascular disease, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Inflammatory Bowel Disease: In women with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, the LNG IUS can be used without restrictions.
Ischemic heart disease: The advantages of initiating the LNG IUS generally outweigh the theoretical or proven risks in women who have current ischemic heart disease or a history of ischemic heart disease. However, in women who have already received the LNG IUS, the theoretical or proven risks usually outweigh the advantages of continuation of the LNG IUS.
Liver tumors: In women with focal nodular hyperplasia, the advantages of the LNG IUS generally outweigh the theoretical or proven risks. However, in women with hepatocellular adenomas or malignant liver tumors, the theoretical or proven risks usually outweigh the advantages.
Malaria: The LNG IUS can be used in women with malaria without any restrictions.
Multiple risk factors for arterial cardiovascular disease: In women with multiple risk factors for arterial cardiovascular disease such as older age, smoking, diabetes and hypertension, the advantages of the LNG IUS generally outweigh the theoretical or proven risks.
Obesity: The LNG IUS can be used in all women irrespective of their weight.
Ovarian Tumors: The LNG IUS can be used without restrictions in women with benign ovarian tumors, including cysts.
Ovarian cancer: The LNG IUS can be used in women with ovarian cancer without any restrictions.
Parity: The LNG IUS can be used in parous women without any restrictions. In nulliparous women, the advantages of the LNG IUS generally outweigh the theoretical or proven risks.
Pregnancy-induced Hypertension: Women with a history of pregnancy-induced hypertension can use the LNG IUS without restrictions.
Pelvic Surgery: Women with a history of pelvic surgery can use the LNG IUS without restrictions.
Past ectopic pregnancy: The LNG IUS can be used in women with past history of ectopic pregnancies without any restrictions.
Pelvic inflammatory disease: (PID) In women with a history of pelvic inflammatory disease with no current risk factors for STIs and a pregnancy subsequent to the PID, the LNG IUS can be used without restrictions. In women with a history of pelvic inflammatory disease with no current risk factors for STIs and without a subsequent pregnancy, the advantages of the LNG IUS generally outweigh the theoretical or proven risks. This is true also in women with IUS already inserted who develop PID. However, the LNG IUS should not be initiated in any woman with a current PID.
Peripartum cardiomyopathy: In women with peripartum cardiomyopathy, the advantages of the LNG IUS generally outweigh the theoretical or proven risks.
Postabortion: The LNG IUS can be used without restriction in women undergoing a first trimester abortion. In women undergoing a second trimester abortion, the advantages of the LNG IUS generally outweigh the theoretical or proven risks. The LNG IUS cannot be used in women immediately post-septic abortions.
Postpartum: The advantages of using the LNG IUS in women within ten minutes after delivery of the placenta or in the interval between ten minutes after delivery of the placenta up to four weeks after delivery of the placenta generally outweigh the theoretical or proven risks. The LNG IUS can be used without restrictions four weeks after delivery. However, the LNG IUS should not be used in cases of puerperal sepsis.
Pregnancy: The LNG IUS cannot be used in pregnant women.
Rheumatoid arthritis: The advantages of initiating the LNG IUS in women already on immunosuppresive therapy generally outweigh the theoretical or proven risks. In women who have the LNG IUS in place before starting the immunosuppresive therapy, the LNG IUS can be continued without restrictions. In women who are not on immunosuppresive therapy, the LNG IUS can be used without restrictions.
Schistosomiasis: The LNG IUS can be used without restrictions.
Severe dysmenorrhea: The LNG IUS can be used without restrictions.
Sexually transmitted infections (STIs): The advantages of continuing an in place LNG IUS in a woman who develops purulent cervicitis or chlamydial infection or gonorrhea generally outweigh the theoretical or proven risks. However, in case a woman currently has these STIs, the LNG IUS should not be initiated. In all other STIs (excluding HIV and hepatitis), vaginitis (including trichomonasvaginalis and bacterial vaginosis) and in women who have an increased risk of STIs, the advantages of using the LNG IUS outweigh the theoretical or proven risks.
Smoking: The LNG IUS can be used without restrictions.
Solid organ transplantation: The LNG IUS should not be initiated in a woman with a complication transplantation. However, if it is already in place, the advantages of continuation of the LNG IUS generally outweigh the theoretical or proven risks. In women with an uncomplicated transplantation, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Stroke: In women with a history of cerebrovascular accident, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Superficial Venous Thrombosis: The LNG IUS can be used without restrictions.
Systemic lupus erythematosus: The LNG IUS should not be used in a woman with SLE with positive (or unknown) antiphospholipid antibodies. In all other women, including women with severe thrombocytopenia and those on immunosuppressive treatment, the advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Thrombogenic mutations: The advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Thyroid disorders: The LNG IUS can be used without restrictions.
Tuberculosis: The LNG IUS can be used without restrictions in non-pevic tuberculosis. However, the LNG IUS should not be used in women with pelvic tuberculosis.
Unexplained vaginal bleeding: The LNG IUS cannot be initiated in a woman with unexplained vaginal bleeding without evaluation. However, the advantages of continuation of use of the LNG IUS in a woman who has the IUS in place and develops unexplained vaginal bleeding generally outweigh the theoretical or proven risks.
Uterine fibroids: The advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Valvular heart disease: The LNG IUS can be used without restrictions.
Vaginal bleeding patterns: The LNG IUS can be used without restrictions in women who have irregular pattern without heavy bleeding. The LNG IUS can be initiated without restrictions in women with heavy or prolonged bleeding. The advantages of continuation of the LNG IUS in women with heavy or prolonged bleeding generally outweigh the theoretical or proven risks.
Viral hepatitis: The LNG IUS can be used without restrictions.
Antiretroviral therapy: The advantages of using the LNG IUS generally outweigh the theoretical or proven risks.
Anticonvulsant therapy: The LNG IUS can be used without restrictions.
Antimicrobial therapy: The LNG IUS can be used without restrictions.
The LNG IUS can be inserted at any time if it is reasonably certain that the woman is not pregnant.
Need for back-up contraception
| • |
If the LNG IUS is inserted within the first 7 days since menstrual bleeding started, no additional contraceptive protection is needed. |
| • |
If the LNG-IUS is inserted >7 days since menstrual bleeding started, the woman needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days. |
Amenorrhea (not Postpartum): The LNG-IUS can be inserted at any time if it is reasonable certain that the woman is not pregnant. The woman needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days.
Postpartum (Including After Cesarean Section): The LNG-IUS can be inserted at any time, including immediately postpartum if it is reasonably certain that the woman is not pregnant. The LNG-IUS should not be inserted in a woman with puerperal sepsis. If the woman is <6 months postpartum, amenorrheic, and fully or nearly fully breastfeeding (exclusively breastfeeding or the vast majority [≥85%] of feeds are breastfeeds), no additional contraceptive protection is needed. Otherwise, a woman who is ≥21 days postpartum and has not experienced return of her menstrual cycle needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days. If her menstrual cycles have returned and it has been >7 days since menstrual bleeding began, she needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days.
Postabortion (Spontaneous or Induced): The LNG-IUS can be inserted within the first 7 days, including immediately postabortion. The LNG-IUS should not be inserted immediately after a septic abortion. The woman needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days unless the IUS is placed at the time of a surgical abortion.
Switching from Another Contraceptive Method: The LNG-IUS can be inserted immediately if it is reasonably certain that the woman is not pregnant. Waiting for her next menstrual period is unnecessary. If it has been >7 days since menstrual bleeding began, the woman needs to abstain from sexual intercourse or use additional contraceptive protection for the next 7 days.
Switching from a Cu-IUD: If the woman has had sexual intercourse since the start of her current menstrual cycle and it has been >5 days since menstrual bleeding started, theoretically, residual sperm might be in the genital tract, which could lead to fertilization if ovulation occurs. A health-care provider can consider providing ECPs at the time of LNG-IUS insertion.
|
| |
|